FINAL ANALYSIS OF A NORDIC LYMPHOMA GROUP PHASE IB/IIA TRIAL OF PIXANTRONE, ETOPOSIDE, BENDAMUSTINE AND, IN CD20‐POSITIVE TUMORS, RITUXIMAB IN RELAPSED AGGRESSIVE B‐ OR T‐CELL LYMPHOMAS

Saved in:
Bibliographic Details
Published inHematological oncology Vol. 39; no. S2
Main Authors d'Amore, F, Leppä, S, Relander, T, Larsen, T. S, Brown, P, Jørgensen, J, Mannisto, S, Lugtenburg, P, Leivonen, S.‐K, Holte, H, Fagerli, U. M, Lauritzsen, G. F, Meyer, P, Minotti, G, Menna, P, Liestøl, K, Toldbod, H
Format Journal Article
LanguageEnglish
Published Chichester Wiley Subscription Services, Inc 01.06.2021
Subjects
CD20 antigen
Etoposide
Immunotherapy
Lymphoma
Monoclonal antibodies
Rituximab
T-cell lymphoma
Targeted cancer therapy
Tumors
Online AccessGet full text

Cover

More Information
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.151_2880